Physician profile
Muhammad Naeem
NPI 1043201668
$3,544.65
in general payments reported to CMS, 2019-2025
26 companies · $244 in 2025
The $244 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $192 · 2021: $527 · 2022: $716 · 2023: $835 · 2024: $910 · 2025: $244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,989.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,049.51 | 2020-2025 | |
| Qol Medical, LLC | $435.75 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $380.98 | 2020-2025 | Stelara, Remicade, Simponi Aria |
| Ferring Pharmaceuticals INC. | $240.92 | 2022-2023 | Rebyota |
| Takeda Pharmaceuticals U.S.A., INC. | $212.99 | 2019-2025 | Eohilia, Gattex |
| Celgene Corporation | $209.49 | 2021-2023 | Zeposia |
| Braintree Laboratories, INC. | $146.15 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $142.20 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $98.33 | 2024-2025 | Vowst |
| Nestle Healthcare Nutrition INC. | $74.88 | 2023 | |
| Redhill Biopharma INC. | $73.32 | 2020-2023 | Talicia |
| Lilly USA, LLC | $61.64 | 2024-2025 | Omvoh |
| Genzyme Corporation | $53.81 | 2024 | |
| Pfizer INC. | $50.17 | 2023 | |
| Merck Sharp & Dohme LLC | $49.24 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $43.70 | 2019-2022 | |
| Gilead Sciences, INC. | $37.00 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.29 | 2021-2023 | Xifaxan |
| Ardelyx, INC. | $25.38 | 2024 | Ibsrela |
| Evoke Pharma, INC. | $24.75 | 2020 | |
| Madrigal Pharmaceuticals | $19.07 | 2025 | Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $18.68 | 2024 | Iqirvo |
| Celltrion USA INC. | $18.47 | 2024 | Vegzelma |
| Amag Pharmaceuticals, INC. | $15.45 | 2019 | |
| Boston Scientific Corporation | $15.27 | 2025 | Cre Pro |
| Ironwood Pharmaceuticals, INC | $15.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Naeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.